TD Asset Management Inc. cut its stake in TherapeuticsMD Inc (NASDAQ:TXMD) by 21.9% during the second quarter, according to its most recent filing with the SEC. The fund owned 427,770 shares of the company’s stock after selling 120,130 shares during the period. TD Asset Management Inc. owned approximately 0.21% of TherapeuticsMD worth $2,254,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of the company. Managed Account Services Inc. boosted its position in shares of TherapeuticsMD by 5.5% in the second quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock valued at $101,000 after buying an additional 1,000 shares during the period. Greenwood Capital Associates LLC boosted its position in shares of TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock valued at $146,000 after buying an additional 3,022 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in shares of TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock valued at $207,000 after buying an additional 10,330 shares during the period. Carl Domino Inc acquired a new position in shares of TherapeuticsMD during the second quarter valued at $235,000. Finally, Oppenheimer & Co. Inc. boosted its position in shares of TherapeuticsMD by 94.5% in the first quarter. Oppenheimer & Co. Inc. now owns 41,466 shares of the company’s stock valued at $298,000 after buying an additional 20,148 shares during the period.
Shares of TherapeuticsMD Inc (TXMD) opened at 6.04 on Wednesday. The company’s market cap is $1.23 billion. The firm’s 50-day moving average is $5.50 and its 200-day moving average is $5.53. TherapeuticsMD Inc has a 1-year low of $3.50 and a 1-year high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. The firm had revenue of $4.25 million for the quarter, compared to the consensus estimate of $4.91 million. During the same period in the previous year, the business earned ($0.11) earnings per share. The company’s revenue for the quarter was down 3.4% compared to the same quarter last year. On average, equities analysts forecast that TherapeuticsMD Inc will post ($0.42) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “TD Asset Management Inc. Sells 120,130 Shares of TherapeuticsMD Inc (TXMD)” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/23/td-asset-management-inc-sells-120130-shares-of-therapeuticsmd-inc-txmd.html.
Several equities analysts have recently weighed in on TXMD shares. Deutsche Bank AG started coverage on shares of TherapeuticsMD in a research note on Friday, July 21st. They issued a “buy” rating and a $10.00 price objective on the stock. Jefferies Group LLC set a $15.00 price objective on shares of TherapeuticsMD and gave the stock a “buy” rating in a research note on Wednesday, June 14th. Stifel Nicolaus restated a “buy” rating and set a $20.00 target price on shares of TherapeuticsMD in a research note on Wednesday, May 24th. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a research note on Friday, August 4th. Finally, Oppenheimer Holdings, Inc. set a $10.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a research note on Thursday, August 17th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. TherapeuticsMD presently has a consensus rating of “Buy” and an average target price of $16.14.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.
